Lung carcinoids with high proliferative activity: Further support for the identification of a new tumor category in the classification of lung neuroendocrine neoplasms.


Journal

Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805

Informations de publication

Date de publication:
10 2020
Historique:
received: 13 01 2020
revised: 16 07 2020
accepted: 03 08 2020
pubmed: 12 9 2020
medline: 22 6 2021
entrez: 11 9 2020
Statut: ppublish

Résumé

Highly proliferative lung carcinoids (HPLC) have been recently reported but information about this subset remains scarce. Clinical and pathological data of 630 patients with lung carcinoids (LC) referred to Gustave Roussy Institute (GR) and European Institute of Oncology (IEO) were retrospectively reviewed to select HPLC and analyze their frequency, behavior and compare their outcome to conventional LC with Ki-67 ≤ 20 % and mitotic count (MC)≤10/2 mm Selection criteria were: diagnosis of LC confirmed by local pathologist, and available clinical and follow-up data. Patients with Ki-67 > 20 % and/or MC > 10/ 2 mm2 in primary or metastatic specimens were identified as HPLC. 30/514 patients (6%) met the selection criteria of HPLC. Based on primary tumor evaluation, 22/25 (88 %) were classified as atypical carcinoids (AC). Median MC was 4.5/2 mm This study confirms the existence and rarity of HPLC. Their characteristics and clinical behavior are more similar to LC rather than neuroendocrine carcinomas (NECs), suggesting that this entity could be managed accordingly.

Identifiants

pubmed: 32916569
pii: S0169-5002(20)30562-6
doi: 10.1016/j.lungcan.2020.08.001
pii:
doi:

Substances chimiques

Ki-67 Antigen 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

149-158

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

M Rubino (M)

Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy; Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

J Y Scoazec (JY)

Department of Pathology and Laboratory Medicine, Gustave Roussy and Paris Saclay University, 114 Rue Edouard Vaillant, 94800, Villejuif, France.

E Pisa (E)

Division of Pathology, European Institute of Oncology, Milan, Italy.

M Faron (M)

Department of Surgical Oncology, Gustave Roussy, Cancer Campus, 114 Rue Edouard Vaillant, 94805, Villejuif, Cedex, France.

L Spaggiari (L)

Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy.

J Hadoux (J)

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

F Spada (F)

Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy.

D Planchard (D)

Medical Oncology, Gustave Roussy Institut, France.

C A Cella (CA)

Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy; Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.

S Leboulleux (S)

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

F De Marinis (F)

Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy.

M Ducreux (M)

Medical Oncology, Gustave Roussy Institut, France.

L Lamartina (L)

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France.

E Baudin (E)

Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94800 Villejuif, France. Electronic address: Eric.BAUDIN@gustaveroussy.fr.

N Fazio (N)

Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumors, European Institute of Oncology, IEO, IRCCS, Milan, Italy. Electronic address: nicola.fazio@ieo.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH